US Penny Stocks To Watch In November 2024

In This Article:

As the U.S. stock market reaches record highs, fueled by a post-election rally and optimism surrounding interest rate cuts, investors are exploring various opportunities to capitalize on this momentum. Penny stocks, though often overlooked and considered a relic of past market days, remain an intriguing investment area for those seeking potential growth in smaller or lesser-known companies. By focusing on penny stocks with strong financial health and clear growth trajectories, investors might uncover promising opportunities that align with today's dynamic market conditions.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.78

$5.56M

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$170.72M

★★★★★★

Flexible Solutions International (NYSEAM:FSI)

$4.37

$51.05M

★★★★★★

RLX Technology (NYSE:RLX)

$1.60

$2.07B

★★★★★★

AsiaFIN Holdings (OTCPK:ASFH)

$0.97

$79.11M

★★★★★★

PHX Minerals (NYSE:PHX)

$3.35

$128.93M

★★★★★☆

So-Young International (NasdaqGM:SY)

$1.25

$88.26M

★★★★☆☆

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71M

★★★★★★

Puma Biotechnology (NasdaqGS:PBYI)

$3.30

$141.37M

★★★★★★

CBAK Energy Technology (NasdaqCM:CBAT)

$1.015

$96.23M

★★★★★☆

Click here to see the full list of 738 stocks from our US Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Bitcoin Depot

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Bitcoin Depot Inc. operates a network of cryptocurrency kiosks across North America and has a market cap of $102.86 million.

Operations: The company's revenue is primarily generated from its data processing segment, totaling $629.50 million.

Market Cap: $102.86M

Bitcoin Depot Inc., with a market cap of US$102.86 million, operates in the volatile penny stock space and has shown mixed financial performance. Despite being unprofitable, it reported a net income of US$11.26 million for Q2 2024, reversing a loss from the previous year. The company's short-term assets exceed both its short- and long-term liabilities, indicating solid liquidity management. However, shareholder dilution occurred over the past year, and its share price remains highly volatile. Recent strategic moves include seeking M&A opportunities and changing auditors to Wolf & Company amid delayed SEC filings.

NasdaqCM:BTM Revenue & Expenses Breakdown as at Nov 2024
NasdaqCM:BTM Revenue & Expenses Breakdown as at Nov 2024

Taysha Gene Therapies

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Taysha Gene Therapies, Inc. is a gene therapy company that develops and commercializes adeno-associated virus-based treatments for monogenic diseases of the central nervous system, with a market cap of $307.41 million.